Sanofi, GSK variant-specific COVID shot found effective against Omicron
Posted on AllSides June 24th, 2022
From The Center
PARIS/LONDON, June 24 (Reuters) - Late-stage data on an experimental COVID-19 vaccine from Sanofi (SASY.PA) and GSK (GSK.L) has showed the shot confers protection against the Omicron variant of the virus, the companies said on Friday.
The so-called bivalent vaccine targets the Beta variant - first identified in South Africa - as well as the original Wuhan strain of the virus.
In a trial involving 13,000 adults, the vaccine demonstrated an efficacy rate of 64.7% against symptomatic COVID, and 72% efficacy against infections specifically caused by the Omicron variant.
When used in people who...